Cisplatin-induced downregulation of OCTN2 affects carnitine wasting

Clinical Cancer Research

Volumn 16, Issue 19, 2010, Pages 4789-4799

  Lancaster, Cynthia S ^a   Hu, Chaoxin ^a,e   Franke, Ryan M ^a   Filipski, Kelly K ^a,d   Orwick, Shelley J ^a   Chen, Zhaoyuan ^a,f   Zuo, Zhili ^b   Loos, Walter J ^c   Sparreboom, Alex ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b CURTIN UNIVERSITY   (Australia)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d NATIONAL CANCER INSTITUTE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f TDM Pharmaceutical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCARNITINE; CARNITINE; CISPLATIN; OCTAMER TRANSCRIPTION FACTOR 1; OCTAMER TRANSCRIPTION FACTOR 2; OCTN2 PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG TRANSPORT; DRUG URINE LEVEL; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; KIDNEY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; URINALYSIS; URINARY EXCRETION; WILD TYPE;

ACETYLCARNITINE; ANIMALS; CARNITINE; CARRIER PROTEINS; CELL LINE; CISPLATIN; DOWN-REGULATION; GENE EXPRESSION PROFILING; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; ORGANIC CATION TRANSPORT PROTEINS; PPAR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77957558268     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1239     Document Type: Article

References (49)

1. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008;73:994-1007. (Pubitemid 351543900)
2. Filipski KK, Loos WJ, Verweij J, Sparreboom A. Interaction of cisplatin with the human organic cation transporter 2. Clin Cancer Res 2008;14:3875-80.
3. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 2009;86:396-402.
4. Ciarimboli G, Deuster D, Knief A, et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 2010;176:1169-80.
5. Heuberger W, Berardi S, Jacky E, Pey P, Krahenbuhl S. Increased urinary excretion of carnitine in patients treated with cisplatin. Eur J Clin Pharmacol 1998;54:503-8. (Pubitemid 28487369)
6. Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet 2006;142:77-85.
7. Nalecz KA, Miecz D, Berezowski V, Cecchelli R. Carnitine: transport and physiological functions in the brain. Mol Aspects Med 2004;25:551-67. (Pubitemid 39195076)
8. Ohtani Y, Nishiyama S, Matsuda I. Renal handling of free and acylcarnitine in secondary carnitine deficiency. Neurology 1984;34:977-9. (Pubitemid 14076471)
9. Scaglia F, Wang Y, Singh RH, et al. Defective urinary carnitine transport in heterozygotes for primary carnitine deficiency. Genet Med 1998;1:34-9. (Pubitemid 128631165)
10. Koizumi T, Nikaido H, Hayakawa J, Nonomura A, Yoneda T. Infantile disease with microvesicular fatty infiltration of viscera spontaneously occurring in the C3H-H-2(0) strain of mouse with similarities to Reye's syndrome. Lab Anim 1988;22:83-7.
11. Lu K, Nishimori H, Nakamura Y, Shima K, Kuwajima M. A missense mutation of mouse OCTN2, a sodium-dependent carnitine cotransporter, in the juvenile visceral steatosis mouse. Biochem Biophys Res Commun 1998;252:590-4. (Pubitemid 28556821)
12. Goto S, Yoshida K, Morikawa T, Urata Y, Suzuki K, Kondo T. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Cancer Res 1995;55:4297-301.
13. Hu S, Franke RM, Filipski KK, et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008;14:3141-8.
14. Perry JL, Dembla-Rajpal N, Hall LA, Pritchard JB. A three-dimensional model of human organic anion transporter 1: aromatic amino acids required for substrate transport. J Biol Chem 2006;281:38071-9. (Pubitemid 46042110)
15. Ginalski K, Elofsson A, Fischer D, Rychlewski L. 3D-Jury: a simple approach to improve protein structure predictions. Bioinformatics 2003;19:1015-8.
16. Huang Y, Lemieux MJ, Song J, Auer M, Wang DN. Structure and mechanism of the glycerol-3-phosphate transporter from Escherichia coli. Science 2003;301:616-20.
17. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994;22:4673-80.
18. Henikoff S, Henikoff JG. Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci U S A 1992;89:10915-9.
19. Inano A, Sai Y, Kato Y, Tamai I, Ishiguro M, Tsuji A. Functional regions of organic cation/carnitine transporter OCTN2 (SLC22A5): roles in carnitine recognition. Drug Metab Pharmacokinet 2004;19:180-9.
20. Seth P, Wu X, Huang W, Leibach FH, Ganapathy V. Mutations in novel organic cation transporter (OCTN2), an organic cation/carnitine transporter, with differential effects on the organic cation transport function and the carnitine transport function. J Biol Chem 1999;274:33388-92.
21. Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR 1996;8:477-86.
22. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T. Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos 2004;32:479-83.
23. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006;319:879-86.
24. Diao L, Ekins S, Polli JE. Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing. Pharm Res 2009;26:1890-900.
25. Leone R, Fracasso ME, Soresi E, et al. Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin. Cancer Chemother Pharmacol 1992;29:385-90.
26. Haschke M, Vitins T, Lude S, et al. Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. Nephrol Dial Transplant ;25:426-33.
27. Ganapathy ME, Huang W, Rajan DP, et al. β-Lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem 2000;275:1699-707.
28. Ohtani Y, Matsuda I. Valproate treatment and carnitine deficiency. Neurology 1984;34:1128-9.
29. Holme E, Greter J, Jacobson CE, et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet 1989;2:469-73.
30. Kano T, Kato Y, Ito K, Ogihara T, Kubo Y, Tsuji A. Carnitine/organic cation transporter OCTN2 (Slc22a5) is responsible for renal secretion of cephaloridine in mice. Drug Metab Dispos 2009;37:1009-16.
31. Hockenberry MJ, Hooke MC, Gregurich M, McCarthy K. Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. J Pediatr Hematol Oncol 2009;31:664-9.
32. Mancinelli A, D'Iddio S, Bisonni R, Graziano F, Lippe P, Calvani M. Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. Cancer Chemother Pharmacol 2007;60:19-26.
33. Portilla D, Dai G, McClure T, et al. Alterations of PPARα and its coactivator PGC-1 in cisplatin-induced acute renal failure. Kidney Int 2002;62:1208-18.
34. Wu X, Huang W, Prasad PD, et al. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther 1999;290:1482-92.
35. Obici S, Feng Z, Arduini A, Conti R, Rossetti L. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. Nat Med 2003;9:756-61.
36. Wolfgang MJ, Kurama T, Dai Y, et al. The brain-specific carnitine palmitoyltransferase-1c regulates energy homeostasis. Proc Natl Acad Sci U S A 2006;103:7282-7.
37. Chang B, Nishikawa M, Sato E, Utsumi K, Inoue M. L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys 2002;405:55-64.
38. Aleisa AM, Al-Majed AA, Al-Yahya AA, et al. Reversal of cisplatin-induced carnitine deficiency and energy starvation by propionyl-L-carnitine in rat kidney tissues. Clin Exp Pharmacol Physiol 2007;34:1252-9.
39. Martinez G, Costantino G, Clementi A, et al. Cisplatin-induced kidney injury in the rat: L-carnitine modulates the relationship between MMP-9 and TIMP-3. Exp Toxicol Pathol 2009;61:183-8.
40. Sayed-Ahmed MM, Eissa MA, Kenawy SA, Mostafa N, Calvani M, Osman AM. Progression of cisplatin-induced nephrotoxicity in a carnitine-depleted rat model. Chemother 2004;50:162-70.
41. Tufekci O, Gunes D, Ozogul C, et al. Evaluation of the effect of acetyl L-carnitine on experimental cisplatin nephrotoxicity. Chemotherapy 2009;55:451-9.
42. Franke RM, Kosloske AM, Lancaster CS, et al. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl- β-D-glucosaminidase. Clin Cancer Res 2010;16:4198-206.
43. Wen G, Ringseis R, Eder K. Mouse OCTN2 is directly regulated by peroxisome proliferator-activated receptor α (PPARα) via a PPRE located in the first intron. Biochem Pharmacol 2010;79:768-76.
44. Pabla N, Murphy RF, Liu K, Dong Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol 2009;296:F505-11.
45. Liu H, Baliga R. Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int 2003;63:1687-96.
46. Bragado P, Armesilla A, Silva A, Porras A. Apoptosis by cisplatin requires p53 mediated p38α MAPK activation through ROS generation. Apoptosis 2007;12:1733-42.
47. Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol 2005;289:F166-74.
48. Ramesh G, Reeves WB. TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;110:835-42.
49. Kim MS, Sweeney TR, Shigenaga JK, et al. Tumor necrosis factor and interleukin 1 decrease RXRα, PPARα, PPARγ, LXRα, and the coactivators SRC-1, PGC-1α, and PGC-1β in liver cells. Metabolism 2007;56:267-79.